Inhibitory modulation of cytochrome c oxidase activity with specific near-infrared light wavelengths attenuates brain ischemia/reperfusion injury

Thomas H. Sanderson1,2,3,4, Joseph M. Wider2,4,5, Icksoo Lee6,7, Christian A. Reynolds1,4,5, Jenney Liu6, Bradley Lepore1, Renée Tousignant1, Melissa J. Bukowski1,5, Hollie Johnston6, Alemu Fite6, Sarita Raghunayakula1,2, John Kamholz6, Lawrence I. Grossman6,4, Karin Przyklenk1,4,5 & Maik Hüttemann6,4

The interaction of light with biological tissue has been successfully utilized for multiple therapeutic purposes. Previous studies have suggested that near infrared light (NIR) enhances the activity of mitochondria by increasing cytochrome c oxidase (COX) activity, which we confirmed for 810 nm NIR. In contrast, scanning the NIR spectrum between 700 nm and 1000 nm revealed two NIR wavelengths (750 nm and 950 nm) that reduced the activity of isolated COX. COX-inhibitory wavelengths reduced mitochondrial respiration, reduced the mitochondrial membrane potential (ΔΨm), attenuated mitochondrial superoxide production, and attenuated neuronal death following oxygen glucose deprivation, whereas NIR that activates COX provided no benefit. We evaluated COX-inhibitory NIR as a potential therapy for cerebral reperfusion injury using a rat model of global brain ischemia. Untreated animals demonstrated an 86% loss of neurons in the CA1 hippocampus post-reperfusion whereas inhibitory NIR groups were robustly protected, with neuronal loss ranging from 11% to 35%. Moreover, neurologic function, assessed by radial arm maze performance, was preserved at control levels in rats treated with a combination of both COX-inhibitory NIR wavelengths. Taken together, our data suggest that COX-inhibitory NIR may be a viable non-pharmacologic and noninvasive therapy for the treatment of cerebral reperfusion injury.

Cardiac arrest impairs systemic perfusion and renders the brain and other organs ischemic. The brain is highly reliant on a constant supply of oxygen and nutrients and thus is particularly sensitive to the resultant deficit in blood flow. In the absence of rapid resuscitation and restoration of blood flow, ischemia leads to severe neurologic damage. While resuscitation is required to preserve neurologic function, it also initiates reperfusion injury, which plays a major role in the compromised recovery of resuscitated patients, and is thought to contribute significantly to the high incidence of morbidity and mortality associated with cardiac arrest. Despite advances in cardiopulmonary resuscitation, neurologic function – a primary metric for clinical outcome – remains poor following cardiac arrest and resuscitation.

1Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, 48201, USA. 2Department of Emergency Medicine, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. 3Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. 4Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA. 5Department of Physiology, Wayne State University School of Medicine, Detroit, MI, 48201, USA. 6Department of Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, 48201, USA. 7College of Medicine, Dankook University, Cheonan-si, Chungcheongnam-do, 31116, Republic of Korea. Correspondence and requests for materials should be addressed to T.H.S. (email: thsand@med.umich.edu) or M.H. (email: mhuttema@med.wayne.edu)
Excessive reactive oxygen species (ROS) generation from the mitochondrial electron transport chain (ETC) was proposed as a principal mechanism of neuronal cell death during reperfusion. The ETC is a series of four protein complexes that utilize energy from electron donors to pump protons across the inner mitochondrial membrane to establish the mitochondrial membrane potential ($\Delta \Psi_m$), which powers ATP synthesis. The activity of the ETC complexes is controlled by $\Delta \Psi_m$, and, in particular, by post-translational modifications to maintain optimal intermediate $\Delta \Psi_m$ values between 120–140 mV, which allow efficient energy production with minimal ROS generation (reviewed in 2,3). Importantly, as $\Delta \Psi_m$ hyperpolarizes beyond the physiological range (>140 mV), ROS production at ETC complexes I and III increases exponentially 4–6.

Ischemia causes energy depletion and excessive calcium release, which is a major signal for mitochondrial activation and global dephosphorylation of mitochondrial proteins 8,9. We and others have proposed that calcium-activated dephosphorylations promote hyperactivation of the ETC complexes, resulting in prolonged hyperpolarization of $\Delta \Psi_m$ and generation of ROS during reperfusion when oxygen, the terminal ETC substrate, reenters the ischemic tissue 4,10. Accordingly, if ROS generation could be reduced during reperfusion, the consequences of ischemia/reperfusion (I/R) injury could be substantially ameliorated. In fact, reducing ROS damage is the goal of many proposed therapies for I/R injury 11. However, pharmacological approaches to address ROS damage suffer from a fundamental limitation: effective drug concentrations in at-risk tissue rely on delivery via blood flow that is only established upon reperfusion.

Our aim was to provide a novel means of protecting the brain from I/R injury by developing therapeutic near infrared light (NIR) as a potential neuroprotective strategy for preserving neurologic function following cardiac arrest and resuscitation. As NIR delivery is not dependent on cerebral perfusion, such a non-invasive therapeutic approach has the potential to circumvent this barrier to early intervention for reperfusion.

In the current study, we have discovered two NIR wavelengths that partially inhibit COX activity in vitro and investigated their ability to interrupt the mechanisms responsible for neuronal cell death caused by reperfusion injury. Most notably, we report that suppression of COX activity with 750 nm and/or 950 nm NIR reduces mitochondrial respiratory rate and $\Delta \Psi_m$ prevents ROS generation in stress states including during reperfusion, and provides robust neuroprotection in an animal model of global brain I/R injury.

Results

Identification of COX-inhibitory NIR. We systematically screened the NIR electromagnetic spectrum in the “therapeutic window of opportunity” of 700 nm to 1000 nm, where NIR absorptions by water and blood are minimal, allowing deep tissue penetration of the NIR for possible medical applications. We integrated a light-protected oxygen electrode chamber into a double beam spectrophotometer (see Materials and Methods), which contained regulatory-competent bovine COX purified under conditions preserving the physiological regulatory properties of the enzyme, such as posttranslational modifications (Fig. 1A). While the NIR frequencies were scanned, COX activity was measured simultaneously. In contrast to previous studies concluding that NIR consistently activates COX 12,17–22, we identified two novel wavelength ranges (750 nm and 950 nm) that inhibit COX activity (Fig. 1B).
LEDs that cover the NIR range in 5–10 nm increments are commercially available and may be useful for medical applications. We obtained 750 nm and 950 nm low power diodes and we also included 810 nm diodes as a control wavelength since it has the opposite effect on COX. Since the diodes have a broader bandwidth (about ±30 nm) compared to the 8 nm bandwidth used in our scan, we first confirmed the effect of the LED emitted NIR on purified COX in vitro by fitting them into the windows of the light-protected oxygen electrode chamber. We observed inhibition of COX by 750 and 950 nm NIR in the range of 5–6%, whereas 810 nm NIR activated the enzyme to a similar extent (Fig. 1C). Interestingly, simultaneous irradiation with 750 and 950 nm NIR resulted in an additive effect, producing a 10% reduction in COX-specific O₂ consumption rate.

**NIR modulates mitochondrial respiration.** To establish the effect of NIR on mitochondria, we next isolated intact mitochondria. Mitochondrial respiration, shown as a % of basal respiratory rate, was reduced by NIR irradiation at 750 and 950 nm in the range of 24–25%, whereas 810 nm NIR increased mitochondrial oxygen consumption (Fig. 1D). Simultaneous irradiation with 750 and 950 nm NIR reduced mitochondrial respiration by 34%. Interestingly, the inhibitory effect of both 750 nm and 950 nm IRL was more pronounced in isolated mitochondria compared to purified COX. It should be noted that the percent change seen in mitochondrial respiration and isolated COX activity cannot be directly compared because the enzymatic environment is fundamentally different, including the presence of supercomplexes in intact mitochondria and, more importantly, the mitochondrial membrane potential, which itself is COX-inhibitory but absent when the purified and detergent-solubilized enzyme is analyzed.

**COX-inhibitory NIR lowers the mitochondrial membrane potential.** Multiple studies have suggested that COX is the rate-limiting step in mitochondrial ETC. We therefore hypothesized that COX-inhibitory NIR is protective in conditions of mitochondrial hyperactivity during conditions of stress. Since COX together with ETC complexes I and III generates ΔΨₘ, a reduction of ETC flux should lead to a reduction of ΔΨₘ. Therefore, we investigated the effect of NIR treatment in HT22 cells, an immortalized line of cultured hippocampal neurons. These studies utilized fluorescent reporters which precluded analysis with shorter wavelengths (750 nm and 810 nm) that can potentially influence the excitation/emission spectra of red fluorophores. NIR treatment, applied via an LED array chip, transiently reduced ΔΨₘ during irradiation in HT22 hippocampal neurons (Fig. 2A, red bar, as shown with 950 nm NIR) and withdrawal of irradiation resulted in a rapid restoration of ΔΨₘ. Oxygen-glucose deprivation (OGD) resulted in increased ΔΨₘ during early reoxygenation (30 min) in HT22 cells; importantly, COX-inhibitory NIR treatment prevented this increase in ΔΨₘ (Fig. 2B).

**NIR limits ROS production and cell death in vitro.** HT22 cells respond to glutamate exposure with a well-established burst of mitochondrial ROS and cell death through a form of oxidative stress-induced apoptosis termed oxytosis. To determine if NIR mediates mitochondrial ROS induced cell death independent of oxygen deprivation, we treated HT22 cells with glutamate with and without NIR treatment. As above, NIR treatment is limited to a longer wavelength (950 nm) to avoid interaction of the treatment wavelength with the excitation/emission spectra of the fluorescent reporter (MitoSOX). Glutamate exposure produced a significant 8-fold increase in MitoSOX fluorescence. NIR irradiation limited this increase in MitoSOX fluorescence in glutamate-exposed cells (Fig. 3A and B).

The neuroprotective effect of NIR in HT22 cells was evaluated using a 60-minute OGD exposure followed by reoxygenation. OGD and reoxygenation caused neuronal death in the control cells detected as a loss of calcein-AM (green) fluorescence and an increased number of cells with disrupted plasma membrane detected with ethidium homodimer-1 (red) fluorescence. In contrast, treatment with inhibitory NIR wavelengths (750 nm and 950 nm) rescued neurons from cell death. Importantly, and as predicted by our model, stimulatory NIR with ethidium homodimer-1 (red) fluorescence. In contrast, treatment with inhibitory NIR wavelengths (750 nm and 950 nm) rescued neurons from cell death. Importantly, and as predicted by our model, stimulatory NIR 810 nm) provided no protection against OGD and reoxygenation (Fig. 3C and D).

**NIR limits ROS production following global brain ischemia.** ROS generated during reperfusion is a primary cause of neurologic I/R injury. Reperfusion following ischemia (ΔΨₘ) hyperpolarization occurs and ROS are generated. To demonstrate if COX is hyperpolarization following ischemia, we harvested brain tissue from control rats, rats that were subjected to 8 min of ischemia, and rats that underwent 8 min of ischemia followed by reperfusion. We measured COX specific activity in the solubilized brain samples and found it to be significantly increased during ischemia and during reperfusion after ischemia (Fig. 4C). We propose that these changes are an underlying cause of ΔΨₘ hyperpolarization observed in vivo during reperfusion. To test the effect of NIR on reperfusion-mediated ROS generation we analyzed MitoSOX fluorescence, which allows detection of mitochondrial superoxide generation in vivo. Eight min of transient global brain ischemia followed by 30 min of reperfusion (Fig. 4A) caused a nearly seven-fold increase in MitoSOX fluorescence and thus ROS accumulation in the CA1 region of the hippocampus (Fig. 4D and E, middle panel, I/R group). Noninvasive transcranial illumination using an LED array chip (Fig. 4B) with COX-inhibitory NIR prevented ROS accumulation, with ROS levels in the NIR treatment group comparable to the sham-surgery control cohort (Fig. 4D and E, compare top panel (sham) with bottom panel (I/R + NIR)).

**NIR treatment is neuroprotective.** Transient global brain ischemia caused by cardiac arrest results in a neurological injury, the hallmark of which is neuronal cell death and atrophy of the CA1 region of the hippocampus. Animals were randomly enrolled into a treatment-blinded study design, as detailed in Fig. 5A. LED-treatment diodes were coupled with heat sinks and fans (Fig. 4B) to prevent diode heating. These modifications were adequate to prevent brain temperature increase during NIR irradiation (Fig. 5B). Transient global ischemia caused a marked reduction in the CA1 neuron population, shown in Fig. 5C by cresyl violet cell staining and the neuN fluorescent neuronal marker. Gliosis occurs following neurologic damage, characterized by infiltration of inflammatory cells to the site of the injury. I/R injury caused accumulation of microglia and macrophages.
(Iba-1 immunofluorescent marker) and astrocytes (GFAP) seen in the CA1 by confocal imaging. Treatment with the COX-inhibitory wavelengths (750 nm or 950 nm), or a combination of the two wavelengths, significantly attenuated neuronal loss in the CA1 region. The I/R cohort exhibited an 88% loss of neurons in the CA1 hippocampus at 14 days post-reperfusion, whereas the inhibitory NIR treatment groups showed neuronal loss ranging from only 11% to 35%. As an important control, treatment with stimulatory NIR (810 nm), did not provide neuroprotection in the CA1 hippocampus (Fig. 5D).

**Delayed treatment with NIR.** These data demonstrate significant tissue protection when NIR is applied at the onset of reperfusion. It is important to note that clinical application of NIR therapy at the time of resuscitation is feasible for certain applications; however, some implementation barriers may make a delayed treatment more clinically realistic. Therefore, we also evaluated how delaying treatment up to 60 min after reperfusion would affect neuroprotection. We found 78% cell survival when 750 nm-950 nm NIR was applied at reperfusion vs. 64% when applied after 1 h of reperfusion, demonstrating significant neuroprotection with delayed administration compared to untreated controls (Fig. 5F).

**Neurobehavioral improvement with NIR.** Ultimately, the goal of preventing I/R injury in the brain is to improve cognitive function following cardiac arrest and resuscitation. Thus, using radial arm maze testing, we examined the effect of NIR on neurobehavioral function using the NIR treatment (750 nm + 950 nm), which is most effective at inhibiting COX, reducing mitochondrial respiration, and provided robust neuroprotection in the histologic studies (Figs. 1C and D, 5C and D). Following I/R, animals had an increase in navigation errors. Improvement of neurobehavioral function after dual wavelength (750 nm + 950 nm) treatment improved performance to the level of the sham-operated cohort (Fig. 5E).

**Discussion**

NIR has gained increasing attention as both a diagnostic and therapeutic tool, and has obvious clinical advantages: NIR therapy is (1) non-invasive, (2) immediately effective and reversible, (3) non-pharmaceutical/non-chemical, and (4) proven safe for human treatment. NIR between 700–1000 nm readily permeates mammalian tissue because photon absorption by water and hemoglobin is minimal at these wavelengths,

![Figure 2. Effect of NIR on mitochondrial membrane potential in cultured HT22 cells. (A) Analysis of the mitochondrial membrane potential (ΔΨm) during irradiation with 950 nm NIR in live cells using the probe TMRM (n = 3, time in min). (B) Analysis of ΔΨm during the first 30 min of reoxygenation after 1 h O2/glucose deprivation [OGD] imaged in live cells using the probe JC-1. Data are mean values of 96 well live cell fluorescence readings.](image-url)
the brain. Photobiomodulation has been tested as a potential approach for multiple therapeutic applications including nerve regeneration, peripheral neuropathy, stroke, and wound healing. However, some results have been contradictory or failed to show clinical efficacy. This may, in part, be explained by different treatment approaches, for example utilizing different energies or duration of the treatment, treatment during different phases of injury progression, or even similar total energies used but applied for different durations can lead to conflicting results. Another limitation is that most studies have focused on a single or very few wavelengths (rather than performing a more comprehensive spectral analysis) when investigating photobiomodulation by NIR. Finally, most studies have shown that NIR exclusively stimulates COX activity and mitochondrial respiration.

In this study, to further our understanding of photobiomodulation, we used a novel approach to uncover specific NIR wavelengths, which directly affect COX activity. We measured oxygen consumption with isolated COX while scanning the spectrum of wavelengths in the near infrared range. We confirm that an established photostimulatory wavelength (810 nm) had the predicted effect of stimulating enzyme activity. In addition, and contrary to the common finding that NIR causes COX activation, we report that 750 and 950 nm NIR suppressed oxygen consumption by COX. Moreover, combined irradiation with the inhibitory wavelengths further reduced COX activity. Our findings demonstrate that specific wavelengths can have a distinct impact on COX activity. With our identified inhibitory wavelengths, we have established a new tool for normalizing hyperactive mitochondrial function, such as during reperfusion following ischemia.

COX-inhibitory but not COX-activating NIR provided protection against ischemia/reperfusion injury in neurons and intact brain. Nonetheless, the precise mechanisms by which tissues benefit from NIR therapy has not been fully characterized. Previous studies reported that NIR could provide neurologic benefit through activation of COX by stimulating controlled release of ROS and subsequent recruitment of antioxidant defenses, or promote ATP synthesis, providing relief from energy depletion during ischemia. NIR was also reported to activate angiogenesis, to increase COX levels, and to modulate protein synthesis and activity. The latter proposals may be relevant and applicable to later phases of I/R injury, for example to aid in tissue repair and remodeling, but cannot explain the acute consequences of NIR observed in the current study.

Our data supports a model, in which inhibitory NIR prevents hyperpolarization of \( \Delta \Psi_m \) during reperfusion, thus preventing ROS generation, the primary cause of neuronal death in I/R injury. The relationship of \( \Delta \Psi_m \) and ROS production is not linear; indeed, when \( \Delta \Psi_m \) exceeds 140 mV ROS generation increases exponentially. Consequently, even a relatively small reduction of \( \Delta \Psi_m \) through NIR-mediated inhibition of COX would result in a large reduction of ROS. Consistent with our model, we report that treatment of HT22 cells with COX-inhibitory NIR reduces \( \Delta \Psi_m \) (Fig. 2A) and that NIR treatment during reperfusion after global brain ischemia prevented accumulation of mitochondrial localized ROS in vivo, as seen in untreated hippocampi.
To verify that the clinical benefit was, in fact, a corollary of neuroprotection from NIR treatment, we measured spatial learning and memory function in rat cohorts. Strikingly, dual wavelength treatment, which is highly neuroprotective, improved navigation performance of the radial arm maze to control levels (Fig. 5E).

In conclusion, we report that NIR therapy is an effective treatment for global brain ischemia. NIR treatment provides a safe, non-invasive option for preventing I/R injury in the brain, with clear clinical advantages because it eliminates the production of ROS rather than trying to scavenge ROS already generated, thereby circumventing the inherent limitations of pharmacological treatments of reperfusion injury, which rely on blood flow. We propose that novel photo-suppressive NIR wavelengths reduce neurological injury by inhibiting COX, which prevents ΔΨm hyperpolarization during reperfusion, thus reducing cytotoxic ROS generation (Fig. 6). We argue that timing of treatment, together with the application of appropriate NIR wavelengths, are crucial for neuroprotection: inhibitory (but not stimulatory) NIR, applied in the early phase of reperfusion, prevents ROS generation and thus tissue injury and cell death signaling in the setting of global cerebral ischemia.

Materials and Methods

Chemicals, reagents, and light emitting diodes. Chemicals and reagents were obtained from Sigma-Aldrich (St. Luis, Montana, USA) unless otherwise stated. Light emitting diodes (LEDs) were obtained from Roithner Lasertechnik (Vienna, Austria). For animal experiments LED array 60 chips were used (750 nm, LED750-66-60; 810 nm, LED810-66-60; 950 nm, LED950-66-60). Diodes were mounted on heat sinks (black aluminum, 47 × 20 for LED array 60 chips) together with a small fan (EC3010M05X; Evercool, New Taipei City, Taiwan) operated in reverse mode (see Fig. 2B). Diodes were calibrated with an optical power and energy meter (842-PE; Newport, Irvine, California, USA) and operated with an energy density of 200 mW/cm². For oxygraph experiments, low energy single diodes were used bundled in pairs of three diodes for each wavelength and operated at the manufacturer’s recommended power settings (750 nm, LED750-33AU, operated at 1.85 V and 15 mW power output; 810 nm, LED810-xxAU, operated at 1.7 V and 22 mW power output; 950 nm, LED-950-525, operated at 1.5 V and 32 mW power output) and placed into the quartz windows of the light-protected oxygen electrode chamber.

Isolation of regulatory competent COX. Mitochondria and, subsequently, COX were isolated from bovine liver as described in detail61. In brief, mitochondria were purified by differential centrifugation, solubilized with Triton X-100, and ultra-centrifuged. The supernatants, which contain COX, were subjected to DEAE Sephadex ion exchange chromatography.
exchange chromatography (GE Healthcare, Pittsburgh, PA, USA). The eluted fractions containing COX were supplemented with cholate following ammonium sulfate fractionation. Purified COX was stored frozen at −80 °C until use. Before activity measurements were performed, COX was dialyzed in the presence of ATP and bovine heart cardiolipin to remove cholate bound to nucleotide binding sites on COX, and to replace cardiolipin that was damaged or lost during COX isolation, respectively. COX purity was confirmed by high resolution urea/SDS-PAGE.

### Measurement of COX activity

COX activity was analyzed as described with the following modifications. Measurements were performed in a final volume of 1 mL in a closed, light-protected oxygen electrode chamber equipped with a micro Clark-type oxygen electrode and closable quartz windows for light application (DW2/2 chamber, Oxygraph system, Hansatech). Experiments were carried out with COX (200 nM) at 20 °C in the presence of 20 mM ascorbate and 1 μM cow heart cytochrome c in 50 mM KH₂PO₄ (pH 7.4), 1% Tween 20, 10 mM KF, 2 mM EGTA. Oxygen consumption was recorded on a computer and analyzed with the Oxygraph plus software. Turnover number is

---

**Figure 5.** (A) Experimental timeline for NIR therapeutic trials. (B) Changes in brain temperature during NIR irradiation with LED diode. (C) CA1 hippocampal ischemia/reperfusion damage is robustly ameliorated upon NIR treatment during reperfusion. [bottom row] 10× image of Cresyl violet stained hippocampus, [middle row] 40× magnification of CA1 hippocampus, [top row] Triple-label immuno-fluorescence for NeuN (red-neuron marker), Iba-1 (green-microglia/macrophage marker), and GFAP (magenta-astrocyte marker). [Left column] Sham-operated animal (Sham), [center column] 8 min ischemia followed by 14 days reperfusion (I/R), [right column] I/R plus NIR treatment (I/R + 950 nm). (D) Neuron counts in the CA1 hippocampus (mean ± SEM, n = 8–12 per group; *p < 0.05. (E) Radial arm maze performance (n = 10 per group; *p < 0.05 compared to sham). (F) Effect of delaying NIR treatment 30 or 60 min after reperfusion (30 R and 60 R; n = 6/group, *p < 0.05 compared to untreated I/R group).
defined as oxygen consumed (μmol)/(s·COX (μmol)). For the wavelength scan experiments the DW2/2 chamber was
integrated into a double beam spectrophotometer (V-570, equipped with an infrared light source; Jasco, Easton, MD,
USA) and scans were performed covering the range of 700 to 1000 nm using a scan speed of 20 nm/min and a band-
width of 8 nm while oxygen consumption rate was recorded. A trend-line was fitted using the moving average function
in Microsoft Excel. COX specific activity in brain tissue homogenates was determined as described63.

Mitochondrial respiration measurements. Rat livers were freshly harvested following mitochondria
isolation as described above. The effect of NIR on intact mitochondrial respiration was analyzed using the same
protocols as described for COX. Mitochondria were diluted to a final concentration of 2 mg/mL in measuring
buffer (120 mM KCl, 5 mM KH$_2$PO$_4$, 3 mM HEPES, 1 mM EGTA, pH 7.2). Following baseline measurements,
10 mM Na-pyruvate and 3 mM malate were added as substrates, oxygen consumption rate (OCR) was recorded
for 2 min after which NIR (same energy settings as above) was turned on and applied for 2 min while continuously
monitoring OCR. Turnover number is defined as the amount of oxygen consumed (nmol/min per mg protein).
OCR after substrate addition was set to 100% and changes during IRL treatment are reported as % change.

Mitochondrial membrane potential changes. HT22 murine hippocampal neurons were used for all
in vitro experiments84. Cells were plated on glass-bottom culture dishes and experiments were conducted in an
inverted Axio Observer microscope (Zeiss, Oberkochen, Germany). TMRM (20µM, Molecular Probes, Waltham, MA, USA) was added to the culture media 30 min prior to imaging. Cells were visualized at 40× magnification and exposures were taken every 30 seconds for the duration of the experiment (approximately 30 min). Cells were irradiated with NIR of 950 nm low energy single diodes (950 nm, LED-950-525, operated at 50 mW power output) for 2 min then NIR was turned off for another 2 min. The z-stacks were set with images collected per 1 µm optical section. Velocity software (Perkin Elmer) was used for image acquisition. Images were

Figure 6. Model of neuroprotection via inhibition of cytochrome c oxidase (COX) with infrared light (NIR)
during reperfusion. Activity of COX is down-regulated (controlled) via phosphorylation under normal
conditions (yellow “P” on COX and cytochrome c). During ischemia, COX becomes dephosphorylated but
cannot operate due to the lack of O$_2$, while NADH and succinate accumulate. At the onset of reperfusion
and in the presence of O$_2$, the ETC operates at maximal activity, creating pathologically high mitochondrial
membrane potentials ($\Delta \Psi_m$), which leads to reverse electron flux, excessive ROS production at ETC complexes
I and III, and mitochondrial loss. Transient inhibition of COX with NIR during reperfusion prevents $\Delta \Psi_m$
hyperpolarization, the production of ROS, and thus cell death (adapted from Sanderson et al. 2013).
evaluated in Volocity software for changes in fluorescence over time, and normalized to control non-irradiated cells. Endpoints with fluorescence measurement (JC-1, TMRM, and MitoSOX) are restricted to one of the 2 identified inhibitory-NIR wavelengths, 950 nm. 750 nm and 810 nm NIR interferes with the excitation/emission spectra for these fluorescent indicators and thus precluded us from testing these wavelengths for parallel effects.

**Glutamate Toxicity in HT22 Neurons.** Glutamate toxicity assay was used to interrogate the effect of NIR on ROS generation. HT22 cells were incubated with 5 mM glutamate and 2.5 mM MitoSOX for 8 h as described[31]. Cells were imaged on a Zeiss inverted fluorescence microscope at 20× and at a Z-plane interval of 0.6 μm. For each treatment group, ten spatially distinct and randomly chosen 2-channel (bright-field and fluorescence) images were obtained. Each image was extracted from fifteen sequential micrographs along the Z-axis with extended depth of focus rendered through ZenPro Imaging Software (Carl Zeiss AG). All images were analyzed after subtracting background with ImageJ (NIH). ROS was measured as the integrated density of MitoSOX fluorescence, normalized to the number of cells and averaged for each experiment. Fold-change was calculated by comparing each treatment to the respective group control (NIR-treated or untreated cells without glutamate).

**Oxygen Glucose Deprivation.** To model ischemia-like conditions in vitro, cells were exposed to transient oxygen and glucose deprivation (OGD)[32–34]. In brief, the culture medium was replaced with serum- and glucose-free medium bubbled with 95% N₂ and 5% CO₂. The glucose media-deprived cultures were then placed in a Bilups-Rothenberg (Del Mar, CA, USA) modular hypoxic chamber, which was flushed for 10 min with 95% N₂ and 5% CO₂ and then sealed. The chamber was placed in a water-jacketed incubator at 37 °C for 60 min and then returned to 95% air, 5% CO₂ and glucose-containing medium for the period of time indicated in each experiment. Control normoglycemic cultures were incubated for the same periods of time at normoxic conditions. Cell death was assessed by incubating cells with Calcein-AM to detect active metabolism (green = live; red = dead) and Ethidium Homodimer 1 to detect disrupted plasma membrane (red nuclei = dead) (Invitrogen Live/Dead). Random sampling of eight regions of interest were imaged at 20× and live and dead cells were quantified by blinded investigators. Cell death/survival is presented as the ratio of live/dead cells. For evaluation of mitochondrial membrane potential (ΔΨm) changes after OGD, we preincubated a separate cohort with the ratiometric JC-1 (2 μg/mL, Molecular Probes, Waltham, MA, USA). Excitation at 488 nm and fluorescence emission at 525 nm and 590 nm were recorded in a fluorescent plate reader (Molecular Devices) and reported as the ratio 590 nm/525 nm intensity.

**Model of global brain ischemia.** Animal use protocols were approved by the Wayne State University Institutional Animal Care and Use Committee and all experiments were performed in accordance with the IACUC protocol and relevant regulations. Global brain ischemia and reperfusion was induced in Sprague Dawley rats as previously described by our lab[35–38], using the method commonly referred to as the 2-vessel occlusion/hypotension model of brain ischemia[39–42]. Briefly, the carotid arteries were isolated through a ventral midline incision and transiently occluded with vascular clips. To aid in reduction of cerebral blood flow during the ischemic phase. Reperfusion is induced by removal of the carotid clips and re-infusion of withdrawn blood. The model of global brain ischemia produces a well-documented reduction of cerebral blood flow in this model measured with laser Doppler flow[43]. In addition, standard changes in hemodynamics[44], brain temperature, blood gasses[45] and blood glucose[46] are documented in our previous studies.

**Administration of NIR treatment.** NIR was administered by direct illumination through the intact scalp and skull via LEDs placed 1.5 cm from the dorsal scalp. Power density at the scalp surface was 50 mW/cm². This placement was optimized to produce no measurable increase in brain temperature (<0.1 °C, measured with implanted thermocouples, Fig. 5B). The scalp was shaved and a drop of glycerol was applied to the shaved area to aid NIR penetration[47]. Animals were treated with (1) the COX-inhibitory NIR wavelength 750 nm; (2) the COX-inhibitory 950 nm wavelength; (3) combined administration of both inhibitory wavelengths, or, as a control, (4) the COX-excitatory wavelength, 810 nm (n = 7–12 per group). NIR irradiation was initiated at the onset of reperfusion and was continued for 120 min.

**Randomization of Animals to Experimental/Treatment Groups.** Experimental group allocation was determined utilizing a blinded/randomized study design. Target group enrollment number was determined by power analysis based on effect size in our previous neuroprotection studies. This protocol was driven by a registrar who is neither one of the surgeons nor the investigator responsible for tissue analysis. The surgeon began the experiment by enrolling a rat and surgically preparing the animal for global brain ischemia. The registrar used a random number generator to determine group allocation of sham-operated control, I/R − untreated, I/R + 750 nm, I/R + 810 nm, I/R + 950 nm, or I/R + 750 nm/950 nm. The registrar initiated treatment with light diodes or dummy diodes in the case of untreated controls. A numbering system is used to identify treatment allocation in the lab record that was known only to the registrar until unblinding after data quantification. The brains were processed and analyzed by a technician provided only the animal number and no group allocation details. Animals that died or were euthanized prior to the predetermined endpoint of the study were not included in the histologic evaluation (sham-operated control: 0/11, I/R − untreated: 8/17, I/R + 750 nm: 2/11, I/R + 810 nm: 2/11, I/R + 950 nm: 1/8, or I/R + 750 nm/950 nm: 0/8). Once data acquisition was finalized, the resultant neuron counts were unblinded and organized into treatment groups for statistical analysis.

**Histological Assessment.** At 14 days of reperfusion, anesthetized animals were transcardially perfused with PBS, then perfusion-fixed with 4% paraformaldehyde in PBS. The brain was removed, cut into 5 mm-thick...
coronal blocks, and postfixed in 4% paraformaldehyde in PBS for 2 h. Blocks were cryoprotected in 30% sucrose in PBS for 24–48 h. The hippocampal formation was serially sectioned between 2.1 and 3.3-mm posterior to bregma at a thickness of 20 μm in the coronal plane and mounted onto slides, air-dried overnight, and then stained with cresyl violet. From the original set of sections, a total of 3 slides were selected from −2.3, −2.5, and −2.7 posterior to bregma, totaling 9 slides per animal. Digital images were taken of the CA1 hippocampal under light microscopy at 40× magnification. To eliminate counting bias, 300 μm-long sections of CA1 hippocampus were randomly chosen, and neuron counts for each image were performed by 2 investigators blinded to the study group and to each other’s counts. Inter-rater reliability, determined by calculating the correlation coefficient between the ratings of the two observers, was found to be 0.99. Only cells that were morphologically identified as CA1 pyramidal neurons and that had a visible nucleus were counted. Neurons showing clear accumulation of globular materials in the cytoplasm, evidence of nuclear fragmentation, shrunken perikarya, or darkly stained nuclei of reduced size were not counted as viable neurons.

**Immunofluorescence.** After 8 min of ischemia followed by 14 days of reperfusion, rat brains were fixed and analyzed by triple-label immunofluorescence as previously described36. Primary antibodies for Iba-1 (ab5076, Abcam, Cambridge, MA, USA), GFAP (ab16997, Abcam), and neuronal nuclei (NeuN, MAB377, Millipore, Billerica, MA, USA) were used to identify microglia, astrocytes, and neurons, respectively. Primary antibodies were labeled with Alexa Fluor conjugated secondary antibodies Alexa Fluor −488, −647, and −546. Immunofluorescence images were acquired on a Leica (Wetzlar, Germany) LMS510 confocal microscope, under a 63× oil-immersion objective. A series of 10 optical sections was taken every 0.25 μm in the z-plane, stacked into z-stacks of 2.5 μm, and shown as a z-projection of the total z-stack using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

**In situ detection of ROS with MitoSOX.** Mitochondrial ROS generation was detected in vivo using the fluorescent indicator MitoSOX (Molecular Probes). Rats were pretreated with a single bolus of MitoSOX (100 μg) via intravenous infusion 30 min prior to induction of ischemia, subjected to global brain ischemia for 8 min, and underwent reperfusion with or without NIR treatment. At 30 min post-reflow, anesthetized animals were transectionally perfused with PBS, then perfusion-fixed with 4% paraformaldehyde. The brains were cryosectioned as described above and tissue sections were counterstained with DAPI for nuclear identification and imaged on a Leica SP5 confocal microscope.

**Radial Arm Maze.** In a separate cohort of animals subjected to global cerebral ischemia, a radial arm maze (RAM) was used to assess neurologic function. NIR-treatment groups were limited to the best treatment based on the inhibitory effect on COX and histologic studies (950 nm–750 nm). One week following ischemia rats began a mild food restriction to gradually reduce body weight to 80% of the age-adjusted weight prior to the experiment. Two weeks following ischemia rats were placed in an 8-arm Plexiglas maze composed of a central octagonal platform with food rewards placed at the end of each arm of the 8-arm maze (Med Associates, Fairfax, VT, USA). Testing was performed in 2 phases: days 1–7 were the training phase and days 8–14 were considered the testing phase. Errors in the testing phase were recorded when the rat entered an arm where the food reward had already been eaten or entered an un-baited arm. Errors are summed and reported as mean daily error.

**Statistical analysis.** Groups were compared using a one-way ANOVA followed by a Tukey’s HSD test for post hoc analysis.

**References**

1. Toledo-Pereyra, L. H., Lopez-Neblina, F. & Toledo, A. H. Reactive oxygen species and molecular biology of ischemia/reperfusion. *Ann Transplant* 9, 81–83 (2004).
2. Hüttemann, M. et al. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. *J Bioenerg Biomembr* 40, 445–456 (2008).
3. Sanderson, T. H., Reynolds, C. A., Kumar, R., Przyklenk, K. & Hüttemann, M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. *Mol Neurobiol* 47, 9–23, https://doi.org/10.1007/s12035-012-8344-z (2013).
4. Korshunov, S. S., Shkolachev, V. P. & Starkov, A. A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. *FEBS Lett* 416, 15–18 (1997).
5. Liu, S. S. Cooperation of a "reactive oxygen cycle" with the Q cycle and the proton cycle in the respiratory chain–superoxide generating and cycling mechanisms in mitochondria. *J Bioenerg Biomembr* 31, 367–376 (1999).
6. Rottenberg, H., Covian, R. & Trumpower, B. L. Mitochondrial complex I is a major source of mitochondrial calcium in the ischemic brain. *J Biol Chem* 284, 19203–19210, https://doi.org/10.1074/jbc.M109.017576 (2009).
7. Lo, E. H., Moskowitz, M. A. & Jacobs, T. P. Exciting, radical, suicidal: how brain cells die after stroke. *Stroke: a journal of cerebral circulation* 36, 189–192 (2005).
8. Robb-Gaspers, L. D. et al. Integrating cytosolic calcium signals into mitochondrial metabolic responses. *Embo J* 17, 4987–5000 (1998).
9. Hopper, R. K. et al. Mitochondrial matrix phosphoproteome: effect of extra mitochondrial calcium. *Biochemistry* 45, 2524–2536 (2006).
10. Liu, R. R. & Murphy, T. H. Reversible cyclosporin A-sensitive mitochondrial depolarization occurs within minutes of stroke onset in mouse somatosensory cortex in vivo: a two-photon imaging study. *J Biol Chem* 284, 36109–36117 (2009).
11. Slemmer, J. E., Shacka, J. J., Sweeney, M. I. & Weber, J. T. Antioxidant and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. *Curr Med Chem* 15, 404–414 (2008).
12. Wong-Riley, M. T. et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. *The Journal of biological chemistry* 280, 4761–4771 (2005).
13. Pastore, D., Greco, M. & Passarella, S. Specific helium-neon laser sensitivity of the purified cytochrome c oxidase. *International journal of radiation biology* 76, 863–870 (2000).
14. Kuru, T. I. & Afaan'eva, N. I. Cytochrome c oxidase as the primary photosensitizer upon laser exposure of cultured cells to visible and near IR-range light. Dokl Akad Nauk 342, 693–695 (1995).

15. Kuru, T. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. J Photochem Photobiol B 49, 1–17 (1999).

16. Wharton, D. C. & Izagoloff, A. Studies on the Electron Transfer System. Lvii. The near Infrared Absorption Band of Cytochrome Oxidase. J Biol Chem 239, 2036–2041 (1964).

17. Wong-Riley, M. T., Bai, X., Buchmann, E. & Whelan, H. T. Light-emitting diode treatment reverses the effect of TTX on cytochrome oxidase in neurons. Neoreport 12, 3033–3037 (2001).

18. Yu, W., Naim, J. O., McGowan, M., Ippolito, K. & Lanzafame, R. J. Photomodulation of oxidative metabolism and electron chain enzymes in rat liver mitochondria. Photochemistry and photobiology 66, 866–871 (1997).

19. Yeager, R. L. et al. Effects of 670-nm phototherapy on development. Photomed Laser Surg 23, 268–272 (2005).

20. Streeter, J., De Taboada, L. & Oron, U. Mechanisms of action of light therapy for stroke and acute myocardial infarction. Mitochondrion 4, 569–576 (2004).

21. Eells, J. T. et al. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proceedings of the National Academy of Sciences of the United States of America 100, 3439–3444 (2003).

22. Eells, J. T. et al. Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. Mitochondrion 4, 559–567 (2004).

23. Villani, G. & Attardi, G. In vivo control of respiration by cytochrome c oxidase in wild-type and mitochondrial DNA mutation-carrying human cells. Proceedings of the National Academy of Sciences of the United States of America 94, 1166–1171 (1997).

24. Kunz, W. S. et al. Flux control of cytochrome c oxidase in human skeletal muscle. J Biol Chem 275, 27741–27745, https://doi.org/10.1074/jbc.M004833200 (2000).

25. Acín-Pérez, R. et al. An intragenic suppressor in the cytochrome c oxidase I gene of mouse mitochondrial DNA. Human molecular genetics 12, 329–339 (2003).

26. Piccoli, C., Scrima, R., Boffoli, D. & Capitanio, N. Control by cytochrome c oxidase of the cellular oxidative phosphorylation system depends on the mitochondrial energy state. Biochem J 396, 573–583 (2006).

27. Dalmonte, M. E. et al. Control of respiration by cytochrome c oxidase in intact cells: role of the membrane potential. The Journal of biological chemistry 284, 32331–32335, https://doi.org/10.1074/jbc.M109050146 (2009).

28. Fukushima, M., Song, J. H., Choi, J., Choi, H. J. & Zhu, B. T. Mechanism of glutamate-induced neurotoxicity in HT22 mouse hippocampal cells. European Journal of pharmacology 617, 1–11, https://doi.org/10.1016/j.ejphar.2009.06.059 (2009).

29. Li, Y., Maher, P. & Schubert, D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. J Photochem Photobiol B 49, 1–17 (1999).

30. Streeter, J., De Taboada, L. & Oron, U. Mechanisms of action of light therapy for stroke and acute myocardial infarction. Mitochondrion 4, 569–576 (2004).

31. Sanderson, T. H., Raghunayakula, S. & Kumar, R. Release of mitochondrial Opa1 following oxidative stress in HT22 cells. Molecular and Cellular Neuroscience 64, 116–122, https://doi.org/10.1016/j.mcn.2014.12.007 (2015).

32. Villringer, A. & Chance, B. Non-invasive optical spectroscopy and imaging of human brain function. Trends in neurosciences 20, 435–442 (1997).

33. Anderson, R. R. & Parrish, J. A. The optics of human skin. J Invest Derm 77, 13–19 (1981).

34. Zivin, J. A. et al. Effects of low-level laser therapy (LLLT) on the nuclear factor (NF)-kappaB signaling pathway in traumatized muscle cells. Lasers in surgery and medicine 31, 283–288, https://doi.org/10.1002/lsm.10096 (2002).

35. Beek, J. F. et al. Effect of Ga-as laser on the regeneration of injured sciatic nerves in the rat. In Vivo 18, 489–495 (2004).

36. Bae, C. S. et al. Effect of Ga-as laser on the regeneration of injured sciatic nerves in the rat. In Vivo 18, 489–495 (2004).

37. DeLellis, S. L., Carnegie, D. H. & Burke, T. J. Improved sensitivity in patients with peripheral neuropathy: effects of monochromatic near-infrared treatment. Diabetes Care 27, 168–172 (2004).

38. Kunz, W. S. et al. Influence of near-Infrared photenergy during mitochondrial DNA mutation-carrying human cells. J Am Podiatr Med Assoc 95, 143–147 (2005).

39. Lim, J. et al. Effects of low-level light therapy on hepatic antioxidant defense in acute and chronic diabetic rats. Journal of biochemical and molecular toxicology 23, 1–8 (2009).

40. Detaboada, L. et al. Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. Lasers in surgery and medicine 38, 70–73 (2006).

41. Oron, A. et al. Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke; a journal of cerebral circulation 37, 2620–2624 (2006).

42. Oron, A. et al. A novel method for laser irradiation of the brain. Lasers in surgery and medicine 38, 2033–2038, https://doi.org/10.1016/j.jsm.2009.06.022 (2009).

43. Oron, A. et al. Effect of Ga-as laser on the regeneration of injured sciatic nerves in the rat. In Vivo 18, 489–495 (2004).

44. DeLellis, S. L., Carnegie, D. H. & Burke, T. J. Improved sensitivity in patients with peripheral neuropathy: effects of monochromatic infrared photo energy. J Am Podiatr Med Assoc 95, 143–147 (2005).

45. Lim, J. et al. Effects of low-level light therapy on hepatic antioxidant defense in acute and chronic diabetic rats. Journal of biochemical and molecular toxicology 23, 1–8 (2009).

46. Lamp, Y. & et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke; a journal of cerebral circulation 38, 1843–1849 (2007).

47. Yip, S. & Zivin, J. Laser therapy in acute stroke treatment. Stroke; a journal of cerebral circulation 41, 88–91, https://doi.org/10.1161/STROKEAHA.109.547547 (2009).

48. Huang, Y. Y., Chen, A. C., Carroll, J. D. & Hamblin, M. R. Biphasic dose response in low level light therapy. Dose Response 7, 358–383, https://doi.org/10.4161/dsr.7.3.9027 (2009).

49. Silveira, P. C. et al. Evaluation of mitochondrial respiratory chain activity in muscle healing by low-level laser therapy. J Photochem Photobiol B 95, 89–92, https://doi.org/10.1016/j.jphotobiol.2009.01.004 (2009).

50. Rizzi, C. M. et al. Effects of low-level laser therapy (LLLT) on the nuclear factor (NF)-kappaB signaling pathway in traumatized muscle. Lasers in surgery and medicine 38, 704–713, https://doi.org/10.1016/j.jsm.2007.01.001 (2006).
67. Sanderson, T. H., Kumar, R., Sullivan, J. M. & Krause, G. S. Insulin blocks cytochrome c release in the reperfused brain through low-energy laser irradiation. *Antioxidants & Redox Signaling* 4, 785–790, https://doi.org/10.1089/ars.2002.4.785 (2002).

68. Wang, X., Tian, F., Soni, S. S., Gonzalez-Lima, F. & Liu, H. Interplay between up-regulation of cytochrome-c oxidase and hemoglobin oxygenation induced by near-infrared laser. *Sci Rep* 6, 30540, https://doi.org/10.1038/srep30540 (2016).

69. Shefer, G., Barash, I., Oron, U. & Halevy, O. Low-energy laser irradiation enhances de novo protein synthesis via its effects on translation-regulatory proteins in skeletal muscle myoblasts. *Biochim Biophys Acta* 1593, 131–139 (2003).

70. Smith, M. L. and Hazelton, J. L. Laser acupuncture: past, present, and future. *Acta neurologica Scandinavica* 132, 347–352 (2004).

71. Whittaker, P. Laser acupuncture: past, present, and future. *Journal of visualized experiments: JoVE.* 24, e78627, https://doi.org/10.3791/78627 (2013).

Acknowledgements

This work was supported by the U.S. National Institutes of Health grant R01 NS091242, by the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH–16–1–0175, the Ralph C. Wilson Medical Research Foundation, the Wayne State University Technology Commercialization Innovation Programs “New Economy Initiative Technology Development Incubator Grant Program” and the “Michigan Universities Commercialization Initiative Challenge Fund,” an industry collaboration with Somanetics (Troy, MI, USA), and the Wayne State University Cardiovascular Research Institute Pilot Grant Program. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the funding agencies including the Department of Defense or the National Institutes of Health.

Author Contributions

T.H.S. and M.H. conceived the study, and J.W., J.K., C.R., L.I.G., and K.P. assisted with study design. I.L., J.L., H.J., A.F. and M.H. performed isolated enzyme and mitochondrial studies. T.H.S., J.W., R.T., and M.B. performed the in vivo brain ischemia experiments. T.H.S., J.W., S.R. and B.L. performed and analyzed the cell experiments. T.H.S. and M.H. wrote the manuscript, assisted by J.W., J.K., C.R., L.I.G., and K.P.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-21869-x.

Competing Interests: T.H.S. and M.H. are co-founders of Mitovation Inc. that develops infrared light therapy for ischemia/reperfusion injury applications. All other authors declare that they have no conflicts of interest with the contents of this article.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018